On November 15, Cellectis, a French biopharmaceutical company, announced that it has signed a binding follow-on investment agreement with AstraZeneca. AstraZeneca had previously announced its intention to make an additional $140 million equity investment.
Cellectis and AstraZeneca Sign Binding Follow-on Investment Agreement
Nov 15, 2023 15:40
CST Updated
15:40
Cellectis
Cell and Gene Therapy Developer
AstraZeneca
Biopharmaceutical Manufacturer